Daiichi Sankyo has revealed its next 5-year business plan (FY2026-FY2030) that outlines how the company plans to deliver over 2.3 trillion yen in oncology revenue by 2030 and be a global top 5 oncology company by 2035 as part of its larger 2035 Vision to be recognised as a “trusted healthcare innovator transforming the lives of people through science and technology.”

The new 5-year business plan reinforces the enduring purpose of Daiichi Sankyo to contribute to the enrichment of quality of life around the world, and central to this growth strategy is an intensified focus on its mission to create new medicines for patients by leveraging the company’s expertise in science and technology.

Hiroyuki Okuzawa, President and CEO, Daiichi Sankyo, “Our new 5-year business plan represents a defining and transformative phase for Daiichi Sankyo. By leveraging our strengths in science and technology, particularly maximising the value of our established DXd Antibody Drug Conjugate platform and prioritising our efforts to identify new breakthrough generating technologies, Daiichi Sankyo is committed to delivering innovative medicines to patients faster while driving sustainable growth and long-term value for all stakeholders.”

A core ambition of the 5-year business plan is to establish Daiichi Sankyo as a global top 5 oncology company by 2035 as measured by over 3 trillion yen in FY2030 revenue, an increase from 2.1 trillion yen in FY2025 revenue, demonstrating aggressive growth. Operating profit of over 600 billion yen is expected to be achieved by end of fiscal year 2030. Target Earnings Per Share (EPS) is estimated to be over 260 yen in FY2030 with an adjusted Dividend On Equity (DOE) of 10 percent or higher each year and progressive dividends. Operating profit is expected to reach 1 trillion yen in the early 2030s.

To achieve these financial targets, the company will maximise the value of its DXd ADC portfolio and additional oncology pipeline through rapid market penetration of over 20 new indications across 5 medicines by 2030, reaching more than 700,000 new patients annually by 2035.

During FY2026, there are five practice-changing launches planned across the DXd ADC portfolio in various countries/regions globally, including 4 new breast cancer indications for Enhertu and Datroway and the company’s first-ever launch in small cell lung cancer with ifinatamab deruxtecan (I-DXd).

Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc. said, “Enhertu has changed the classification and treatment of breast cancer, becoming the most successful Antibody Drug Conjugate ever by revenue. Datroway, our second DXd Antibody Drug Conjugate, is on its way to changing the treatment paradigm for triple negative breast cancer. By leveraging this extensive expertise, we plan to expand our leadership into lung cancer where there are more than 10 new indication launches planned for this tumor type across our portfolio over the next 5 years.”